To clarify the effects of adding erlotinib to gemcitabine and the roles of EGFR and KRAS mutations as predictive biomarkers in patients with advanced pancreatic cancer who receive these regimens, we performed this open-label, randomized, prospective study. Here, KRAS is linked to familial pancreatic carcinoma.